Linda M. Rubinstein
CFO and Principal Financial & Accounting OfficerMs. Linda M. Rubinstein, MA, is CFO and Principal Financial & Accounting Officer of Nektar Therapeutics from May 15, 2026. She serves as Chief Financial Officer at Diasome Pharmaceuticals, Inc. from September 2026. She has years of operational, financial and capital markets experience across the life sciences industry and investment banking, including as CFO of numerous public and private biotechnology companies. She served as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer at Adverum Biotechnologies, Inc. since December 12, 2022. She served as Principal Financial Officer & Principal Accounting Officer at Alector, Inc. since September 08, 2021 until February 25, 2022. She served as Chief Financial Officer at Alector, Inc. until February 25, 2022 and also served as its Interim Chief Financial Officer since September 08, 2021. She served as Chief Financial Officer of Sublimity Therapeutics Limited since January 2020. She served as Interim Chief Financial Officer at Apexigen Inc. until 2022 and also served as Chief Financial Officer since 2021 until 2021 and served as Interim Chief Financial Officer since November 2018 until 2021. She served as Independent Director of Biocept, Inc., since July 20, 2021 until October 13, 2023. She served as an Interim Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of Five Prime Therapeutics Inc. since April 13, 2018 until November 26, 2018. She served as Consulting Chief Financial Officer at Retrotope Inc. Ms. Rubinstein has been a Partner of FLG Partners, LLC since September 7, 2010. As a Partner of FLG Partners, Ms. Rubinstein’s consulting Chief Financial Officer roles have included ArmaGen, EpiBiome, iPierian (acquired by BMS), True North and Tunitas. Ms. Rubinstein served as the Chief Financial Officer and Executive Vice President of PaxVax, Inc. since March 2014. She served as Chief Financial Officer and Senior Vice President of Ingenuity Systems Inc., which was acquired by QIAGEN in 2013. She served as Vice President & Chief Financial Officer of Solexa Inc., (which was acquired by Illumina in 2007) since April 2005 and also served as its Secretary & Principal Accounting Officer. Prior to that, Ms. Rubinstein was a Principal at RDJ Advisors. Prior to that, she was in a similar position at ChemoCentryx, where she developed and implemented the financial strategy. Her consulting practice focuses on assisting private life science companies to formulate and execute financing and strategic plans. She served as Secretary of Lynx Therapeutics Inc. She was a Senior Banker at Lehman Brothers and called on public and private West Coast biotechnology companies, advising them on financings, mergers and acquisitions and strategic collaborations. Prior to specializing in Biotechnology, Ms. Rubinstein covered the broader healthcare industry as well as companies within the general industrial, mortgage banking and selected other sectors. Prior to joining Lehman Brothers in 1993, she worked with Scully Brothers and Foss and Merrill Lynch Capital Markets in New York and the American-Israel Chamber of Commerce in Los Angeles. Ms. Rubinstein has served as chief financial officer, consulting chief financial officer or financial advisor to multiple biotechnology companies, including Kezar Life Sciences, Inc., Medikine, Inc., RenovoRx, Inc., Sublimity Therapeutics Holdings Ltd., True North Therapeutics, Inc. and Tunitas Therapeutics, Inc. She served as a Director at Sensorin, Inc. from 2007 to 2015. She served as a Member of the Advisory Board at Axiom Venture Partners, L.P. Ms. Rubinstein holds an M.A. and B.A. degree in Economics from University of California, Los Angeles, where she graduated summa cum laude and Phi Beta Kappa.
Positions
- Company NameNektar TherapeuticsStock CodeNKTRPositionCFO and Principal Financial & Accounting OfficerColleagues
- HWHoward W. RobinCEO, President & Director
- RBRobert B. ChessIndependent Chairman of the Board
- JZJonathan ZalevskySenior VP and Chief Research & Development Officer
- JBJason BarnardChief Accounting Officer
- EZElizabeth ZhangVP of Legal, Corporate Counsel & Secretary
- RARoy A. WhitfieldLead Independent Director
- RSR. Scott GreerIndependent Director
- DMDiana M. BrainardIndependent Director
